GLP-1/GIP technical reference
Tirzepatide in Mexico — Dual GLP-1/GIP Agonist for Research
What is Tirzepatide?
Tirzepatide is a synthetic peptide designed as a dual agonist of the GLP-1R and GIPR receptors. GIP (glucose-dependent insulinotropic polypeptide) is an incretin released in response to nutrients, acting on the pancreas, adipose tissue and nervous system. Combining GLP-1 and GIP agonism in a single molecule enables researchers to study whether two coordinated incretin signals produce metabolic effects that are superior to — or qualitatively distinct from — isolated GLP-1 agonism. Developed by Eli Lilly, it is approved as a medicine under the brand names Mounjaro® (type-2 diabetes) and Zepbound® (weight management).
Clinical data — SURMOUNT-1 trial
In SURMOUNT-1 (Jastreboff et al., NEJM 2022), the pharmaceutical formulation of Tirzepatide 15 mg weekly was associated with a mean 22.5% body-weight reduction at 72 weeks (treatment-regimen estimate), versus 2.5% in the placebo arm. This positioned Tirzepatide as the dual agonist with the strongest clinical evidence in weight management until the publication of Retatrutide data in 2023.
Tirzepatide vs Semaglutide vs Retatrutide
| Peptide | Receptors | Weight reduction | Study | |
|---|---|---|---|---|
| Tirzepatide | GLP-1R + GIPR | −22.5% (SURMOUNT-1) | Phase 3 | Approved (Mounjaro/Zepbound) |
| Semaglutide | GLP-1R | −14.9% (STEP 1) | Phase 3 | Approved (Ozempic/Wegovy) |
| Retatrutide | GLP-1R + GIPR + GCGR | −24.2% (Phase 2 NEJM) | Phase 3 ongoing | In development |
Note: Cross-trial comparison, not a head-to-head study.
Technical specifications — Peptide Life Tirzepatide
| Parameter | Value |
|---|---|
| Name | Tirzepatide |
| Presentation | Lyophilized vial |
| Purity | ≥99% HPLC-UV 220 nm |
| Identity | ESI-MS ±0.1 Da |
| Storage | −20°C |
| Use | Research Use Only (RUO) |
Frequently asked questions about Tirzepatide in Mexico
+What is Tirzepatide and what is it used for in research?
Tirzepatide is a dual GLP-1/GIP agonist studied in metabolic research. In clinical trials with the pharmaceutical formulation it showed weight reductions of up to 22.5%. Peptide Life supplies it as an RUO material for in vitro scientific research.
+Tirzepatide or Semaglutide: which is more effective?
In separate trials, Tirzepatide showed greater weight reduction (−22.5%) than Semaglutide (−14.9%). No direct head-to-head trial exists. The difference may reflect Tirzepatide's dual GLP-1/GIP agonism.
+How much does research Tirzepatide cost in Mexico?
Check current availability and pricing in the Peptide Life catalog or contact support via WhatsApp.
+Is Mounjaro available in Mexico?
Mounjaro® is the brand name of Tirzepatide approved as a medicine. Peptide Life supplies Tirzepatide as RUO research material, not as a medicine. For medical treatment, consult a certified physician.
+What is the difference between Tirzepatide and Retatrutide?
Tirzepatide activates two receptors (GLP-1R and GIPR). Retatrutide activates three (GLP-1R, GIPR and GCGR). In phase 2, Retatrutide showed greater weight reduction (−24.2% vs −22.5%), but they are separate trials without direct comparison.